Gilteritinib is a second-generation type I tyrosine kinase inhibitor with activity against FLT3 (reviewed in Daver et al, 2019; Hassanein et l, 2016; Lim et al, 2017; Luxkin et al, 2017). This pathway describes FLT3 mutants that are resistant to inhibition by gilteritinib.
Almahayni, MH, Hassanein, M, Ahmed, SO, Gaballa, S, El Fakih, R
Schlenk, RF, Levis, MJ, Daver, N, Russell, NH
Deangelo, DJ, Luskin, MR
Dubielecka, PM, Lim, SH, Raghunathan, VM
© 2023 Reactome